MedTrace Logo

The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19

NCT04341480 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 305

Last updated 2021-10-07

No results posted yet for this study

Summary

A novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) emerged at December 2019 in Wuhan, China, and soon caused a large global outbreak. The delayed treatment for many chronic diseases, due to the concern of SARS-CoV-2 infection, is an increasing serious problem. Here the investigators investigate the safety of chemotherapy for patients with gynecological malignancy in Wuhan, the center of high-risk regions of COVID-19.

Conditions

  • Gynecological Cancer

Interventions

DRUG

Chemotherapy

Routine chemotherapy for individual tumor type.

Sponsors & Collaborators

  • Tongji Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2022-12-10
Completion
2023-01-10

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04341480 on ClinicalTrials.gov